Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Phase 2INBRX-106Neutral

AI Analysis

Summary

Inhibrx will present Phase 2 primary endpoint results for INBRX-106 in first-line HNSCC via webcast on September 8, 2026. The presentation represents a significant clinical milestone for the company's biologic pipeline.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Primary endpoint results to be presented

Importance:7/10

Sentiment:

0.00

Phase 2Data ReadoutHNSCCWebcastPrimary Endpoint Results

Related Companies

$INBX

Read the original article

Published by PR Newswire Biotech on September 4, 2026 8:00 PM

Read Original